ILMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Illumina Inc (ILMN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive financial performance and some encouraging developments, the technical indicators suggest a bearish trend, and there are no strong proprietary trading signals to support immediate action. The stock may be worth monitoring for a better entry point.
The MACD is negative and contracting, RSI indicates the stock is oversold at 13.041, and moving averages are converging. The current pre-market price of $116.18 is near the S1 support level of $115.854, suggesting limited downside risk in the short term but no strong upward momentum.
Illumina reported a 5% YoY revenue increase in Q4 2025, driven by strong clinical consumables performance. Net income surged by 78.61% YoY, and EPS grew by 83.90% YoY. The acquisition of SomaLogic and the appointment of Dr. Eric Green as Chief Medical Officer are expected to enhance market competitiveness.
Gross margin dropped slightly by 0.68% YoY. Technical indicators suggest a bearish trend, and there is no recent congress trading data or strong hedge fund or insider activity to support a bullish case.
In Q4 2025, revenue increased by 4.98% YoY to $1.16 billion. Net income rose significantly by 78.61% YoY to $334 million, and EPS grew by 83.90% YoY to 2.17. However, gross margin slightly declined to 65.49%.
Analysts have mixed views. Piper Sandler lowered the price target to $170 with an Overweight rating. JPMorgan lowered the price target to $120 with a Neutral rating. UBS raised the price target to $135 with a Neutral rating. Evercore ISI and Guggenheim maintain Buy/Outperform ratings with price targets of $150 and $170, respectively. The overall sentiment is cautiously optimistic but not strongly bullish.
